Translating Neurological Efficacy Studies from Rodents to Larger Species

How to select the appropriate animal model to study your compound profiling effects

Abstract artificial intelligence concept background.

You’ve tested your compound in rodents to FDA standards, and everything went well. So why has it failed in clinical studies? More than likely, your success was lost in translation. Efficacy in humans is not guaranteed, but there are steps you can take to improve outcomes. Evaluating your therapy in large animals produces data that is more predictive of how it will perform in clinic. Minimize frustration and prepare for relevant safety toxicology studies further down the line with profiling studies in large animals that more closely represent the human phenotype.

 

Accelerate your Program

Join the experts as they explain the advantages of a translational platform for neuroscience discovery, and learn how using the right models at the right times can increase your chance of success.

 

Presentations

CNS Gene Delivery & Therapy: From Rodents to Larger Species 
Enrique Garea Rodriguez, PhD, Head of Study Directors

Translational Imaging Techniques in Drug Development: From Rodents to NHP to Clinic
Jussi Rytkönen, PhD, Principal Scientist In Vivo

Using Microdialysis for your PK/ PD Studies: Probing Small and Large Molecules
Holden Janssens, PhD, Director In Vivo Pharmacology

CNS Gene Delivery & Therapy: From Rodents to Larger Species
Enrique Garea Rodriguez, PhD, Head of Study Directors

 

Translational Imaging Techniques in Drug Development: From Rodents to NHP to Clinic
Jussi Rytkönen, PhD, Principal Scientist In Vivo

 

Using Microdialysis for your PK/ PD Studies: Probing Small and Large Molecules
Holden Janssens, PhD, Director In Vivo Pharmacology

Enrique Garea Rodriguez, PhD headshot

Enrique Garea Rodriguez, PhD
Head of Study Directors

After 10 years in academia with postdoctoral positions at the University of Freiburg and the German Primate Center, Enrique joined Charles River with the acquisition of Encepharm/Brains-Online. A graduate of the University of Bielefeld, Enrique earned his PhD in neuroscience from the University of Göttingen. Key areas of expertise: drug discovery, CNS disease models, imaging, and gene therapy. Published 9 peer-reviewed research articles.


Jussi Rytkönen, PhD headshot

Jussi Rytkönen, PhD
Principal Scientist In Vivo

Jussi Rytkönen has more than 10 years with Charles River, Finland, where he has progressed from external consultant to research associate and full-time scientist. In his current role, he splits his time between managing a team of experienced neuroscientists and R&D programs where he helps clients move their research efficiently toward the preclinical phase. As subject matter expert in nuclear imaging and radiometric assays in CNS disease models, he is driven to further expanding Charles River’s existing CNS assay capabilities and establishing new client partnerships. Taking an active role in in clients’ integrated drug development programs, Dr. Rytkönen helps them advance novel targets for the treatment of CNS disorders.


Holden Janssens, MSc headshot

Holden Janssens, MSc
Director, In Vivo Pharmacology

Holden Brown Janssens joined Charles River with the acquisition of Brains On-Line in 2017. As the director of the In Vivo Pharmacology group in South San Francisco, Holden Brown Janssens has been instrumental in the growth and expansion of the site’s operations. She earned her PhD in neuroscience from the University of Illinois, Chicago wth research focused on understanding the neural circuity involved in reward and learning utilizing a combination of behavioral and in vivo neurotransmitter monitoring assays.